PsyArXiv Preprints
March 11, 2026
preprint
Letter in reply to Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;doi:10.1001/jama.2025.13481 (unpublished, rejected by the journal)
Psychedelic Medicine
March 1, 2026
Jonah Griffin-Stolbach, Hanna Molla, Donald Hedeker et al.
There has been great interest in the use of very low doses of psychedelic drugs like lysergic acid diethylamide (LSD) to improve mood and cognition. However, controlled studies have thus far provided little support for their efficacy. One challenge is that the subjective effects are subtle and on the threshold of detectability, whereas the questionnaires used to assess the drugs' effects were...
Journal of Pain and Symptom Management
March 1, 2026
William B Alexander, Eric D Hansen, Brian T Anderson et al.
1 citation
Meaning is a primary existential concern in those with advanced illnesses and functions as an important coping mechanism. Loss of meaning contributes to existential distress, and, in particular, may manifest as demoralization, a syndrome of poor coping that is associated with negative outcomes. Psychedelics are unique psychoactive compounds that, among other properties, are proposed to enhance...
Drug and Alcohol Dependence Reports
March 1, 2026
Jing-Jer Chen, Carla J. Berg, Y Tony Yang
1 citation
While interest in the therapeutic and recreational use of hallucinogens has increased, national surveillance often reports use in aggregate, potentially masking shifting trends among pharmacologically distinct substances. This study assessed trends in specific hallucinogens from 2021 to 2023 and identified correlates of use, with particular attention to subgroup patterns in populations commonly...
MacEwan University Student eJournal
February 18, 2026
Jordan Mcdowell, Jada Middleton, Alanna Bluett et al.
In Canada, the use of both prescription medications and psychedelics has become increasingly prevalent. As of 2022, approximately 16.5% of Canadians—about 6.3 million individuals—were prescribed at least one antidepressant, with fluoxetine remaining one of the most commonly used options (IQVIA, 2023). Benzodiazepine use, including drugs like alprazolam, ranges between 5% to 10% nationwide, with...
BJPsych Open
February 12, 2026
David A Bender, Holly Dunn, Amanda Pekau et al.
1 citation
Background The relationship between media portrayal of psychedelic drugs, scientific research and drug policy is an area of debate. Aims To apply artificial intelligence technology to measure trends in media sentiment towards the therapeutic potential of psychedelic drugs. Method Up to 300 of the most relevant articles from Google News searches for the term ‘psychedelics’ were sampled for each...
Cahiers d’Études Italiennes
February 10, 2026
Marie Fabre
The importance of drugs as a theme in the second half of Elsa Morante’s work is rarely emphasized. Beginning with the author’s existential and political turn in the 1960s, a decade that saw her experiment with a series of sedatives and psychedelics, drugs and addiction become omnipresent in the lives of some of the key characters in her novels and short stories. This article focuses on the...
Exploratory Research in Clinical and Social Pharmacy
February 4, 2026
Shreya Shiju, Rohan Tirumala, Elliot Marseille
Background: As public and scientific interest in psychedelics grows, unsupervised use for health purposes is increasing. In the U.S., past-year hallucinogen use nearly doubled from 2015 to 2023. Many individuals report self-treating physical or psychological symptoms without medical supervision using psychedelics—a practice termed self-medication. Despite this trend, review-level syntheses...
Psychiatry Research
February 2, 2026
Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al.
1 citation
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...
Neuroscience & Biobehavioral Reviews
2026
Netta Pinhas, Nofar Eidlman, Avigail Barnea et al.
2 citations
Microdosing - the practice of consuming extremely low doses of classical psychedelic substances that do not elicit overt psychedelic effects - has gained significant attention as a potential method for enhancing cognitive performance. However, findings from controlled studies remain mixed and inconclusive. This preregistered meta-analysis examined the cognitive effects of classical psychedelic...